£109.06

Springer Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways: 15

Price data last checked 37 day(s) ago - refreshing...

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£109 today · cheaper than every other day in the last 2 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey
↓ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 28 days • 28 data points (No recent data available)

Historical
Generating forecast...
£111.97 £108.77 £109.47 £110.17 £110.86 £111.56 £112.26 01 May 2026 07 May 2026 14 May 2026 21 May 2026 28 May 2026

Price Distribution

Price distribution over 28 days • 3 price levels

Days at Price
Current Price
10 days · current 11 days 7 days 0 3 6 8 11 £109 £110 £112 Days at Price

Price Analysis

Most common price: £110 (11 days, 39.3%)

Price range: £109 - £112

Price levels: 3 different prices over 28 days

Description

This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance. From the Back Cover This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance. About the Author Yosef Yarden, PhD, is Professor, Department of Biological Regulation, The Weizmann Institute of Science, Israel.

Product Specifications

Format
paperback
Domain
Amazon UK
Release Date
02 February 2019
Listed Since
02 February 2019

Barcode

No barcode data available

Similar Products You Might Like

Resistance to Tyrosine Kinase Inhibitors (Resistance to Targeted Anti-Cancer Therapeutics)
85% match

Resistance to Tyrosine Kinase Inhibitors (Resistance to Targeted Anti-Cancer Therapeutics)

Springer

£107.98 06 Jun 2026
Resistance to Tyrosine Kinase Inhibitors (Resistance to Targeted Anti-Cancer Therapeutics)
85% match

Resistance to Tyrosine Kinase Inhibitors (Resistance to Targeted Anti-Cancer Therapeutics)

Springer

£107.98 24 May 2026
Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy: Targeted Therapies to Reverse Resistance: 1 (Resistance to Targeted Anti-Cancer Therapeutics, 1)
82% match

Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy: Targeted Therapies to Reverse Resistance: 1 (Resistance to Targeted Anti-Cancer Therapeutics, 1)

Springer

£107.98 24 May 2026
82% match

Molecular Mechanisms of Cancer Resistance: Emerging Technologies and Therapeutic Strategies (Novel approaches to overcome cancer resistance to conventional therapies)

Academic Press

£153.99 22 May 2026
Resistance to Immunotoxins in Cancer Therapy: 6 (Resistance to Targeted Anti-Cancer Therapeutics, 6)
82% match

Resistance to Immunotoxins in Cancer Therapy: 6 (Resistance to Targeted Anti-Cancer Therapeutics, 6)

Springer

£74.57 31 May 2026
Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models
82% match

Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models

Springer

£74.57 05 Jun 2026
Molecular Oncology: Underlying Mechanisms and Translational Advancements
81% match

Molecular Oncology: Underlying Mechanisms and Translational Advancements

Springer

£80.64 24 May 2026
Gene Regulation and Therapeutics for Cancer
81% match

Gene Regulation and Therapeutics for Cancer

CRC Press

£69.94 20 May 2026
Resistance to Molecular Therapies for Hepatocellular Carcinoma: 13 (Resistance to Targeted Anti-Cancer Therapeutics)
80% match

Resistance to Molecular Therapies for Hepatocellular Carcinoma: 13 (Resistance to Targeted Anti-Cancer Therapeutics)

Springer

£107.27 28 May 2026
Pharmaceutical Perspectives of Cancer Therapeutics
80% match

Pharmaceutical Perspectives of Cancer Therapeutics

Springer

£179.99 06 Jun 2026
Cell Signaling & Molecular Targets in Cancer
80% match

Cell Signaling & Molecular Targets in Cancer

Springer

£107.98 14 May 2026
Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal
80% match

Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal

Springer

£179.99 31 May 2026
Systems Biology in Cancer Research and Drug Discovery
80% match

Systems Biology in Cancer Research and Drug Discovery

Springer

£107.98 24 May 2026
Resistance to Targeted Therapies in Breast Cancer: 16 (Resistance to Targeted Anti-Cancer Therapeutics, 16)
80% match

Resistance to Targeted Therapies in Breast Cancer: 16 (Resistance to Targeted Anti-Cancer Therapeutics, 16)

Springer

£80.62 29 May 2026
Drug Targeting Complexity: Tissue-Specific Regulation and Molecular Paradigms in Cancer Therapy
80% match

Drug Targeting Complexity: Tissue-Specific Regulation and Molecular Paradigms in Cancer Therapy

Academic Press

£157.99 23 May 2026
Current Applications for Overcoming Resistance to Targeted Therapies: 20 (Resistance to Targeted Anti-Cancer Therapeutics, 20)
79% match

Current Applications for Overcoming Resistance to Targeted Therapies: 20 (Resistance to Targeted Anti-Cancer Therapeutics, 20)

Springer

£75.68 04 Jun 2026
Cancer Drug Discovery: Science and History
79% match

Cancer Drug Discovery: Science and History

Springer

£109.19 24 May 2026
Molecular Targets and Strategies in Cancer Prevention
79% match

Molecular Targets and Strategies in Cancer Prevention

Springer

£107.33 25 May 2026
Cancer Genetics and Therapeutics: Focus on Phytochemicals
79% match

Cancer Genetics and Therapeutics: Focus on Phytochemicals

Springer

£74.87 24 May 2026
Signal Transduction in Cancer Metastasis: 15 (Cancer Metastasis - Biology and Treatment, 15)
79% match

Signal Transduction in Cancer Metastasis: 15 (Cancer Metastasis - Biology and Treatment, 15)

Springer

£113.77 17 May 2026
Unravelling Cancer Signaling Pathways: A Multidisciplinary Approach
79% match

Unravelling Cancer Signaling Pathways: A Multidisciplinary Approach

Springer

£74.35 06 Jun 2026
Signaling Pathways in Breast Cancer: Molecular Mechanisms, Therapeutic Strategies, and Multidrug Resistance
79% match

Signaling Pathways in Breast Cancer: Molecular Mechanisms, Therapeutic Strategies, and Multidrug Resistance

Academic Press

£145.99 21 May 2026
The Hippo Signaling Pathway and Cancer
79% match

The Hippo Signaling Pathway and Cancer

Springer

£107.98 04 Jun 2026
New Approaches in Cancer Pharmacology: Drug Design and Development: Vol. II: 2 (ESO Monographs)
79% match

New Approaches in Cancer Pharmacology: Drug Design and Development: Vol. II: 2 (ESO Monographs)

Springer

£77.83 31 May 2026